
(ST. LOUIS, MO) — Bayer Group announced Wednesday that it is consolidating its U.S. glyphosate business into a standalone entity, Ruveon LLC.
According to a company press release, the subsidiary “will focus on all aspects of U.S. glyphosate, pricing, go-to-market strategies, production and logistics and will be solely responsible for the U.S. glyphosate business.” Ruveon will be based in St. Louis and the company remains part of Bayer Group but will operate with its own dedicated product and commercial teams, including sales and marketing for Roundup and other glyphosate products sold into agricultural, industrial, turf and ornamental markets.
Bayer framed the move as an execution step within its previously announced Five-Year Framework, a broader plan to reshape the Crop Science division around growth, resilience and profitability. “Today we take an important step within our Five-Year Framework,” said Brian Naber, head of Crop Science North America & Australia/New Zealand. “Ruveon’s launch is a sign of our ongoing commitment to excellence in the glyphosate market.”
Alfonso Alba Ordóñez, a 30-year Bayer veteran with leadership posts across Europe, South America, North America and China, joins Ruveon as chief executive. Steve Knodle, with 28 years in the ag industry, will serve as executive vice president and head of Ruveon’s commercial business.
Bayer described Ruveon as built to be “a more nimble and well-positioned player” in a commodity-based market that “requires a specialized approach to address competitive dynamics.” Bayer and Monsanto remain the only U.S. manufacturer of glyphosate, producing roughly 60% of the glyphosate sold domestically and 40% of global supply. Glyphosate generated $2.4 billion in revenue for Bayer in 2024.
The corporate restructuring lands one week after the U.S. Supreme Court ruled 7-2 in Monsanto v. Durnell that the Federal Insecticide, Fungicide, and Rodenticide Act preempts state failure-to-warn claims when the EPA has reviewed a product and not required a cancer warning on its label. The decision is expected to lead to the dismissal of a large share of the roughly 200,000 Roundup-related claims filed against Bayer since its 2018 acquisition of Monsanto. Bayer said it still intends to proceed with a proposed $7.25 billion class-action settlement to resolve remaining claims.
The news also comes after Bayer/Monsanto and its now-named subsidiary Ruveon LLC filed a petition with the Commerce Department, the U.S. International Trade Commission and the Court of International Trade seeking antidumping and countervailing duties on glyphosate imported from China. The filing alleges Chinese producers are selling glyphosate salts and technical material in the U.S. “at less than fair value,” citing dumping margins on Chinese IPA salts ranging from roughly 69% to more than 446%, based on import data from October 2025 through March 2026.
That petition drew swift pushback from some of the same farm groups that had backed Bayer in the Supreme Court case. Bower called it “highly concerning” and said Bayer was “taking this step purely for benefit of the company and its shareholders… at the expense of the American farmer.” The National Association of Wheat Growers and American Soybean Association raised similar concerns, pointing to prior trade cases — including duties on imported phosphate fertilizer and Corteva’s 2024 case on 2,4-D — that they say raised costs for growers without proportional benefit. ASA said it “strongly opposes” the petition and is reviewing its implications for soybean growers.
According to reporting from DTN/Progressive Farmer, Bayer’s stock jumped more than 8% Thursday to just over $15 a share, up roughly $2 since the Supreme Court ruling. Reuters reported that some analysts see the Ruveon consolidation as a possible precursor to a spinoff or divestment of the glyphosate business, a move that could further insulate Bayer from litigation risk.
You can find more about the company at https://www.ruveon.com.





